March 6, 2008 -- American Oriental Bioengineering (NYSE: AOB) reported that 2007 revenues jumped 46% to $160.5 million. Net income climbed 48% to $43.3 million, or 61 cents per diluted share. Breaking the numbers down by division, prescription pharmaceuticals were up 30% at $59 million, OTC pharma products doubled their year earlier numbers at $68.6 million, and nutraceuticals moved up a small 6% to $32.7 million. AOB’s two acquisitions, CCXA and Boke, added a total of $8.6 million to full-year revenues. The two companies became part of AOB during the late third quarter and fourth quarter of the year. More details...
